RMC-6291 is named as a drug or biological intervention in 2 clinical trials in our USA trial register, 1 of which is recruiting. The lead sponsor is Revolution Medicines, Inc.. Registered phases: Phase 1 and Phase 1/2. Conditions studied include Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer |
Phase 1/2 | Recruiting |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | 1 |
| Colorectal Cancer (CRC) | 1 |
| Pancreatic Ductal Adenocarcinoma | 1 |
| Advanced Solid Tumor | 1 |
| Non-Small Cell Lung Cancer, NSCLC | 1 |
| KRAS, NRAS, HRAS-mutated NSCLC | 1 |
| KRAS G12C-mutated Solid Tumors, Lung Cancer | 1 |
| Lung Cancer Stage IV, Advanced Solid Tumor, Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Revolution Medicines, Inc. | 2 |
| Register | RMC-6291 trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RMC-6291 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RMC-6291 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.